Literature DB >> 12853394

Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies.

Kyung Hyo Kim1, Jigui Yu, Moon H Nahm.   

Abstract

For evaluating pneumococcal vaccines, the opsonophagocytic killing assay (OPKA) is useful as a supplement to the pneumococcal antibody enzyme-linked immunosorbent assay (ELISA). However, evaluations of pneumococcal vaccines require the determination of antibody responses to 7 to 11 serotypes, and the OPKA is tedious to perform and requires more serum than the ELISA. Consequently, the OPKA is infrequently used for evaluating pneumococcal vaccines. To overcome these limitations, we have developed a simple multiplexed (double-serotype) OPKA by using antibiotic-resistant pneumococci for nine serotypes. Serotype 6B, 9V, 19A, and 23F strains were made streptomycin resistant, and serotype 4, 6A, 14, 18C, and 19F strains were made optochin resistant. The multiplexed OPKA was the same as the single-serotype OPKA except for two changes. First, the target bacteria were a mixture of one streptomycin-resistant strain and one optochin-resistant strain. Second, the surviving bacteria of each serotype were enumerated by plating on Todd-Hewitt agar plates with yeast extract and an agar overlay containing the appropriate antibiotics and 2,3,5-triphenyl tetrazolium chloride. The performance of the multiplexed OPKA was evaluated by analyzing 28 serum samples from adults immunized with a 23-valent polysaccharide vaccine by using the single-serotype OPKA and the multiplexed OPKA. The multiplexed OPKA was specific for the desired serotypes. The multiplexed and conventional OPKAs had comparable assay sensitivities and produced results that were highly correlated (r(2) values ranging from 0.92 to 0.98) for all nine serotypes. A simple modification of the conventional OPKA produces a multiplexed assay that greatly reduces effort, reagents, and the necessary amount of serum.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853394      PMCID: PMC164251          DOI: 10.1128/cdli.10.4.616-621.2003

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  28 in total

1.  Development of a multi-specificity opsonophagocytic killing assay.

Authors:  M H Nahm; D E Briles; X Yu
Journal:  Vaccine       Date:  2000-06-01       Impact factor: 3.641

2.  Disc diffusion test in the identification of Candida species.

Authors:  T Menon; K M Ponnuvel
Journal:  Mycoses       Date:  2000       Impact factor: 4.377

3.  Interpreting results from trials of pneumococcal conjugate vaccines: a statistical test for detecting vaccine-induced increases in carriage of nonvaccine serotypes.

Authors:  M Lipsitch
Journal:  Am J Epidemiol       Date:  2001-07-01       Impact factor: 4.897

4.  Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay.

Authors:  N F Concepcion; C E Frasch
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

5.  Comparison of a classical phagocytosis assay and a flow cytometry assay for assessment of the phagocytic capacity of sera from adults vaccinated with a pneumococcal conjugate vaccine.

Authors:  W T Jansen; M Väkeväinen-Anttila; H Käyhty; M Nahm; N Bakker; J Verhoef; H Snippe; A F Verheul
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

6.  A flow cytometric opsonophagocytic assay for measurement of functional antibodies elicited after vaccination with the 23-valent pneumococcal polysaccharide vaccine.

Authors:  J E Martinez; S Romero-Steiner; T Pilishvili; S Barnard; J Schinsky; D Goldblatt; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

7.  Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination.

Authors:  J B Rubins; M Alter; J Loch; E N Janoff
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

8.  Development of a selective differential agar for isolation and enumeration of Campylobacter spp.

Authors:  J E Line
Journal:  J Food Prot       Date:  2001-11       Impact factor: 2.077

9.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.

Authors:  C G Whitney; M M Farley; J Hadler; L H Harrison; C Lexau; A Reingold; L Lefkowitz; P R Cieslak; M Cetron; E R Zell; J H Jorgensen; A Schuchat
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

10.  Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study.

Authors:  Scott A Halperin; Jane McDonald; Lindy Samson; Lisa Danzig; George Santos; Allen Izu; Bruce Smith; Noni MacDonald
Journal:  Clin Invest Med       Date:  2002-12       Impact factor: 0.825

View more
  30 in total

1.  Fluorescent multivalent opsonophagocytic assay for measurement of functional antibodies to Streptococcus pneumoniae.

Authors:  Kathryn T Bieging; Gowrisankar Rajam; Patricia Holder; Ross Udoff; George M Carlone; Sandra Romero-Steiner
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

Review 2.  Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies.

Authors:  R A Fleck; S Romero-Steiner; M H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

3.  Evaluation of multiplex flow cytometric opsonophagocytic assays for determination of functional anticapsular antibodies to Streptococcus pneumoniae.

Authors:  Joseph E Martinez; Elizabeth A Clutterbuck; Han Li; Sandra Romero-Steiner; George M Carlone
Journal:  Clin Vaccine Immunol       Date:  2006-04

Review 4.  Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines.

Authors:  Sandra Romero-Steiner; Carl E Frasch; George Carlone; Roland A Fleck; David Goldblatt; Moon H Nahm
Journal:  Clin Vaccine Immunol       Date:  2006-02

5.  Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.

Authors:  F M Russell; J R Carapetis; R L Burton; J Lin; P V Licciardi; A Balloch; L Tikoduadua; L Waqatakirewa; Y B Cheung; M L K Tang; M H Nahm; E K Mulholland
Journal:  Vaccine       Date:  2010-10-31       Impact factor: 3.641

Review 6.  Pneumococcal vaccine and opsonic pneumococcal antibody.

Authors:  Joon Young Song; M Allen Moseley; Robert L Burton; Moon H Nahm
Journal:  J Infect Chemother       Date:  2013-05-09       Impact factor: 2.211

7.  Poly-N-acetyl-β-(1-6)-glucosamine is a target for protective immunity against Acinetobacter baumannii infections.

Authors:  Leticia V Bentancor; Jennifer M O'Malley; Cagla Bozkurt-Guzel; Gerald B Pier; Tomás Maira-Litrán
Journal:  Infect Immun       Date:  2011-11-21       Impact factor: 3.441

8.  Position of O-Acetylation within the Capsular Repeat Unit Impacts the Biological Properties of Pneumococcal Serotypes 33A and 33F.

Authors:  Brady L Spencer; Jamil S Saad; Anukul T Shenoy; Carlos J Orihuela; Moon H Nahm
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

9.  Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A.

Authors:  Hyunju Lee; Moon H Nahm; Robert Burton; Kyung-Hyo Kim
Journal:  Clin Vaccine Immunol       Date:  2009-01-14

10.  The effect of age on the response to the pneumococcal polysaccharide vaccine.

Authors:  Hyunju Lee; Moon H Nahm; Kyung-Hyo Kim
Journal:  BMC Infect Dis       Date:  2010-03-10       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.